Taaneh is engaged in commercializing the use of diamond particles, an inert material for the authentication, identification and construction of anti-counterfeiting systems.
The technology has applications in diverse sectors including the pharmaceutical industry (particularly solid oral dosage forms), prestige cosmetics and fragrances, foods, textiles, inks, currency, mechanical parts and packaging.
Taaneh's IP and patent positions are designed to protect the technology that is the basis for the company's business plan.
Andrew S. Janoff, Ph.D. (Chief Executive Officer; Director)
Dr. Janoff, Taaneh’s founder, conceived of the Company’s intellectual property. Previously Dr. Janoff was Chairman and Chief Executive Officer of Celator Pharmaceuticals, a Company also based on intellectual property he devised and for which he coordinated $60M in venture funding. Dr. Janoff was also Vice President of Research and Development at Elan Corporation and Vice President and a Scientific Founder of The Liposome Company, Inc., where he led the team that discovered and developed ABELCET. Dr. Janoff has served on various government advisory committees and as an expert consultant for legal firms and pharmaceutical companies, and has testified on patent matters in federal court. In his career, Dr. Janoff has overseen the filing of eight INDs, two NDAs and one MAA in the areas of oncology, anti-infectives and acute respiratory distress syndrome. He was appointed as Adjunct Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University Medical College, and has held visiting scientific appointments at Princeton University in the Departments of Physics, Molecular Biology and Chemical Engineering. Dr. Janoff holds a B.S. in Biology from the American University, an M.S. and Ph.D in Biophysics from Michigan State University, and was a Research Fellow in Anaesthesia at the Massachusetts General Hospital and in Pharmacology at the Harvard Medical School.
Donna Cabral-Lilly, Ph.D. ( Director)
Dr. Cabral-Lilly has over twenty years’ experience in discovery, development and manufacturing of complex pharmaceuticals including solid oral and transdermal dosage forms, solids for local implantation and sterile parenterals. In her career she has been responsible for addressing global regulatory requirements, process and analytical development issues, technology transfer, compliance and due diligence. She has extensive experience in nanoparticle formulations and in pharmaceutical life cycle management from initial discovery through phase 4 commitments. Previously she was Vice President, Pharmaceutical Development at Celator Pharmaceuticals where for over a decade she had overall responsibility for all aspects of pharmaceutical development including clinical batch manufacturing, scale-up, validation, novel method development, GMP analysis, batch release and stability studies. She has held positions of increasing responsibility in pharmaceutical development at The Liposome Company, Elan Pharmaceuticals and Control Delivery Systems. Dr. Cabral-Lilly holds a B.A. in Chemistry from Case Western Reserve University and a Ph.D. in Biochemistry from Boston University. She is a member of the Parenteral Drug Association, Regulatory Affairs Professional Society, American Association of Pharmaceutical Science, and the National Association of Professional Woman.
Don Yarson ( Director)
Mr. Yarson is a highly skilled marketing executive with extensive experience in sales force infrastructure development and management, marketing, product launches and strategic planning. Previously he was Senior Vice President, Commercial Operations at Genzyme Corporation, with responsibilities for directing the activities of 200 employees in sales, marketing, managed markets, operations and patient reimbursement services. He directed the launch of all of Genzyme’s products within its genetic disease franchise, which contributed to over $3 billion in annual sales. Mr. Yarson was also Senior Vice President, Commercial Operations at The Liposome Company where he built a commercial infrastructure and launched ABELCET, which achieved sales in excess of $100M and brought the Company to profitability. In his career, Mr. Yarson has also held positions in marketing at Genentech and Ciba-Geigy Pharmaceuticals. He holds a B.S. in Business from Sacred Heart University in Fairfield , CT.
Laura A. Coruzzi, Ph.D. (Director)
Laura Coruzzi has been listed in the top 10 of America's Best Life Science Litigators by Managing Intellectual Property and as one of the nation's top attorneys by Chambers Global. For close to thirty years her patent procurement practice has focused on protecting new emerging technologies. She has represented clients such as Mount Sinai School of Medicine, Genentech, MedImmune, Bristol-Myers Squibb, Millennium and Sugen regarding patent prosecution, licensing, inferences, strategic planning, portfolio management, portfolio evaluation and due diligence investigations. She was part of the team that secured an important Supreme Court decision for Myriad Genetics in a closely followed and highly publicized patent case. Dr. Coruzzi is admitted to practice in New York as well as before the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit, and the U.S. District Courts for the Southern and Eastern Districts of New York. She is also registered to practice before the U.S. Patent and Trademark office.
John Dempsey (Director)
John Dempsey has more than 30 years’ experience in the pharmaceutical industry. He currently serves as President, Pharmaceutical Sciences at Raintree Oncology Services. Prior to that, Mr. Dempsey was Vice President of the Strategic Customer Group and member of the Management Board for Johnson & Johnson’s North American Pharmaceutical Business. In prior leadership positions for Ortho Biotech, Mr. Dempsey led the Company’s strategic direction to ensure the safety of the biologic supply chain. He has worked with numerous government agencies and has testified before the Surgeon General’s Task Force on Importation. He began his pharmaceutical career as a sales representative for Eli Lilly.
William McCormick (Director)
Mr. William C. McCormick is a Senior Advisor and Member of the Advisory Board of Aequitas Capital Management Inc. and an Advisor of JMW Capital. In addition, Mr. McCormick serves as the Vice Chairman and a Director of TECT Corporation and has been a Director at Merix since October 1997. Mr. McCormick is a Director of Homestead Capital, Brillcast Inc., SP Industries Inc., Albertina Kerr Centers, Consolidated Precision Products, Glacier Bay and WDC Exploration. He serves on the Board of Blue Point Capital and on the Boards of several profit and nonprofit companies. Mr. McCormick is the President at the William C. & Jani E. McCormick Foundation and is a Director of the Technology Transfer Committee of the Providence Hospital System and Portland State University. Mr. McCormick was named as one of the Top 20 Business Leaders of Oregon from 1985 to 2005. He holds a B.S. degree in Mathematics from the University of Cincinnati.
Sol M. Gruner, Ph.D. (Chief Technology Officer)
Sol Gruner is the John L Wetherill Professor of Physics at Cornell University. For 16 years, until 2013, he was also Director of the Cornell High Energy Synchrotron Source with responsibilities for administering its multi-million dollar annual budget and meeting nationally mandated research goals. Dr. Gruner has made seminal contributions in the fields of physics, chemistry, biology and medicine. For his contributions, Dr. Gruner was named a Fellow of the American Physical Society in 1990, and a Fellow of the American Association for the Advancement of Science in 2001. In 2011 he was elected to the American Academy of Arts and Sciences, a leading center for independent policy research and one of the oldest and most prestigious honorary societies in America whose first members included George Washington and Benjamin Franklin. The Academy elects "leaders from academic, business, and government sectors to respond to the challenges facing the nation and the world". In 2012, Dr. Gruner testified before Congress regarding the stewardship of national scientific interdisciplinary facilities and the judicious use of taxpayer dollars in the allocation of research equipment. As Taaneh's Chief Technology Officer, Dr. Gruner will participate in developing the commercial and scientific strategies of the Corporation.
Preventing Food Fraud
January 25, 2016
Anti-Counterfeiting: Diamond-Based Technology
November 5, 2015
Taaneh Announces New Appointments
August 4, 2015